WallStSmart

Coca-Cola European Partners PLC (CCEP)vsZevia Pbc (ZVIA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Coca-Cola European Partners PLC generates 12244% more annual revenue ($20.90B vs $169.33M). CCEP leads profitability with a 9.3% profit margin vs -4.1%. CCEP earns a higher WallStSmart Score of 57/100 (C).

CCEP

Buy

57

out of 100

Grade: C

Growth: 6.7Profit: 7.0Value: 4.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.59

ZVIA

Hold

38

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.0Quality: 6.5
Piotroski: 4/9Altman Z: 0.40
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CCEP.

ZVIAUndervalued (+27.4%)

Margin of Safety

+27.4%

Fair Value

$2.26

Current Price

$1.41

$0.85 discount

UndervaluedFair: $2.26Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEP3 strengths · Avg: 9.3/10
Return on EquityProfitability
42.9%10/10

Every $100 of equity generates 43 in profit

EPS GrowthGrowth
68.3%10/10

Earnings expanding 68.3% YoY

Free Cash FlowQuality
$1.51B8/10

Generating 1.5B in free cash flow

ZVIA3 strengths · Avg: 8.7/10
Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
21.2%8/10

Revenue surging 21.2% year-over-year

Areas to Watch

CCEP4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.2%4/10

0.2% revenue growth

Altman Z-ScoreHealth
1.594/10

Distress zone — elevated risk

Debt/EquityHealth
1.383/10

Elevated debt levels

PEG RatioValuation
2.722/10

Expensive relative to growth rate

ZVIA4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$106.23M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-20.0%2/10

ROE of -20.0% — below average capital efficiency

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEP

The strongest argument for CCEP centers on Return on Equity, EPS Growth, Free Cash Flow.

Bull Case : ZVIA

The strongest argument for ZVIA centers on Debt/Equity, Price/Book, Revenue Growth. Revenue growth of 21.2% demonstrates continued momentum.

Bear Case : CCEP

The primary concerns for CCEP are Revenue Growth, Altman Z-Score, Debt/Equity.

Bear Case : ZVIA

The primary concerns for ZVIA are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

CCEP profiles as a value stock while ZVIA is a growth play — different risk/reward profiles.

ZVIA carries more volatility with a beta of 1.01 — expect wider price swings.

ZVIA is growing revenue faster at 21.2% — sustainability is the question.

CCEP generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

CCEP scores higher overall (57/100 vs 38/100). ZVIA offers better value entry with a 27.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Coca-Cola European Partners PLC

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Coca-Cola Europacific Partners PLC produces, distributes and sells a variety of ready-to-drink non-alcoholic beverages. The company is headquartered in Uxbridge, the United Kingdom.

Visit Website →

Zevia Pbc

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Zevia PBC is an innovative beverage company focused on providing zero-calorie, naturally sweetened drinks that align with the rising consumer trend towards healthier lifestyles and environmental sustainability. The company's diverse portfolio includes sodas, energy drinks, and sparkling waters, all sweetened exclusively with stevia and free from artificial ingredients. With a strong distribution network and a brand ethos centered on health and social responsibility, Zevia is well-positioned for significant growth in the competitive beverage sector, making it an attractive prospect for institutional investors looking to capitalize on the clean-label market trend.

Want to dig deeper into these stocks?